| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 4, 2017Data highlight AmpliPhi's pipeline of bacteriophage-based therapies for resistant bacterial infections
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology,...
-
Mar 27, 2017Positive clinical data and strengthened management team support continued development of novel therapies for antibiotic-resistant infections
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology,...
-
Feb 23, 2017
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections,...
-
Feb 6, 2017
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections,...
-
Jan 30, 2017
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections,...
-
Jan 4, 2017Business update call scheduled for today at 4:30 p.m. Eastern
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections,...
-
Dec 12, 2016
LOS ANGELES, California — December 12, 2016 — C3J Therapeutics, Inc., a private, clinical stage biotechnology company focused on the development and commercialization of novel therapeutics...